JP6787926B2 - 肺高血圧症の治療方法 - Google Patents

肺高血圧症の治療方法 Download PDF

Info

Publication number
JP6787926B2
JP6787926B2 JP2017555438A JP2017555438A JP6787926B2 JP 6787926 B2 JP6787926 B2 JP 6787926B2 JP 2017555438 A JP2017555438 A JP 2017555438A JP 2017555438 A JP2017555438 A JP 2017555438A JP 6787926 B2 JP6787926 B2 JP 6787926B2
Authority
JP
Japan
Prior art keywords
och
compound
pulmonary
alkyl
refers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017555438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502156A5 (enExample
JP2018502156A (ja
Inventor
バット ラックスミナラヤン
バット ラックスミナラヤン
カンティロン マーク
カンティロン マーク
エム．ウォーリス エレン
エム．ウォーリス エレン
ラニ バット シーマ
ラニ バット シーマ
Original Assignee
レビバ ファーマシューティカルズ，インコーポレイティド
レビバ ファーマシューティカルズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レビバ ファーマシューティカルズ，インコーポレイティド, レビバ ファーマシューティカルズ，インコーポレイティド filed Critical レビバ ファーマシューティカルズ，インコーポレイティド
Publication of JP2018502156A publication Critical patent/JP2018502156A/ja
Publication of JP2018502156A5 publication Critical patent/JP2018502156A5/ja
Application granted granted Critical
Publication of JP6787926B2 publication Critical patent/JP6787926B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017555438A 2015-01-12 2016-01-11 肺高血圧症の治療方法 Active JP6787926B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562102470P 2015-01-12 2015-01-12
US62/102,470 2015-01-12
PCT/US2016/012873 WO2016115039A1 (en) 2015-01-12 2016-01-11 Methods for treating pulmonary hypertension

Publications (3)

Publication Number Publication Date
JP2018502156A JP2018502156A (ja) 2018-01-25
JP2018502156A5 JP2018502156A5 (enExample) 2019-02-21
JP6787926B2 true JP6787926B2 (ja) 2020-11-18

Family

ID=56406257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017555438A Active JP6787926B2 (ja) 2015-01-12 2016-01-11 肺高血圧症の治療方法

Country Status (5)

Country Link
US (1) US10441590B2 (enExample)
EP (1) EP3244896B1 (enExample)
JP (1) JP6787926B2 (enExample)
CN (1) CN107206007B (enExample)
WO (1) WO2016115039A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3749324B1 (en) 2017-12-28 2025-11-05 Reviva Pharmaceuticals, Inc. Arylpiperazine compound for use to treat pulmonary fibrosis
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4613598A (en) * 1984-03-13 1986-09-23 Mitsubishi Chemical Industries Limited Piperazine derivatives and their acid addition salts
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
NZ555491A (en) 2005-01-03 2010-01-29 Univ Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
AR063302A1 (es) * 2006-10-13 2009-01-21 Otsuka Pharma Co Ltd Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla.
RU2497819C2 (ru) 2007-05-21 2013-11-10 Ривайва Фармасьютикалс, Инк. Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина
TWI373336B (en) * 2007-06-15 2012-10-01 Univ Kaohsiung Medical Kmup-1 capable of treating hypertension
EP2299814A4 (en) * 2008-05-27 2011-06-15 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR USE OF ANTIPSYCHOTICS ON PIPERAZINE BASIS
MX2011004284A (es) * 2008-10-22 2011-06-21 Sam Amer & Co Inc Metodo para tratar la hipertension arterial pulmonar.
CN102413830A (zh) * 2009-02-26 2012-04-11 雷维瓦药品公司 利用芳基哌嗪衍生物的组合物、合成及方法
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
WO2015157451A1 (en) 2014-04-08 2015-10-15 Reviva Pharmaceuticals, Inc. Methods for treating attention deficit hyperactivity disorder

Also Published As

Publication number Publication date
US20180125851A1 (en) 2018-05-10
EP3244896B1 (en) 2024-06-12
CN107206007B (zh) 2021-08-10
HK1244448A1 (zh) 2018-08-10
EP3244896A4 (en) 2018-08-29
CN107206007A (zh) 2017-09-26
WO2016115039A1 (en) 2016-07-21
JP2018502156A (ja) 2018-01-25
EP3244896C0 (en) 2024-06-12
US10441590B2 (en) 2019-10-15
EP3244896A1 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
ES2892954T3 (es) Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos
US10894043B2 (en) Pharmaceutical composition
CN107206007B (zh) 用于治疗肺高血压的方法
US20190040073A1 (en) Nonanoic and decanoic acid derivatives and uses thereof
US20230061592A1 (en) Methods for treating pulmonary fibrosis
JP2018502157A (ja) アルツハイマー病の治療方法
CN107206006A (zh) 用于治疗与帕金森病相关联的精神病的方法
CN118217290B (zh) 可溶性鸟苷酸环化酶刺激剂在防治高原肺水肿中的用途
HK1244448B (en) Methods for treating pulmonary hypertension
KR20030087074A (ko) 아릴에텐술폰아미드 유도체의 신규 용도
HK40038590A (en) Methods for treating pulmonary fibrosis
CA3036474C (en) Therapeutic agent for an ophthalmic disease comprising a vegf receptor inhibitor
HK40066388A (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK40038590B (en) Methods for treating pulmonary fibrosis
TW202339760A (zh) 用於預防或治療心臟衰竭(hf)之組合物
WO2021203779A1 (zh) 治疗肺动脉高压的化合物及其应用
HK1241361B (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1243061A1 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
JPWO2000018399A1 (ja) 副鼻腔炎の予防および／または治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200820

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201029

R150 Certificate of patent or registration of utility model

Ref document number: 6787926

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250